Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2026)

Xeris Biopharma Holdings has reported Operating Leases for 5 years, with the latest figure at $31.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 20.34% year-over-year to $31.1 million; the trailing twelve-month figure through Mar 2026 stood at $31.1 million (down 20.34% YoY), and the FY2025 full-year result was $31.5 million, down 5.2% from the prior year.
• Operating Leases for Q1 2026 stood at $31.1 million, down from $31.5 million in the prior quarter.
• The five-year high for Operating Leases was $39.7 million in Q3 2024, with the low at $9.4 million in Q4 2022.
• Historically, Operating Leases has averaged $32.0 million across 5 years, with a median of $34.8 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Leases surged 269.75% — and 2026, when it slipped 20.34%.
• Xeris Biopharma Holdings' Operating Leases stood at $9.4 million in 2022, then surged by 269.75% to $34.8 million in 2023, then declined by 4.33% to $33.3 million in 2024, then slipped by 5.2% to $31.5 million in 2025, then fell by 1.5% to $31.1 million in 2026.
• The last three Operating Leases figures came in at $31.1 million (Q1 2026), $31.5 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.